



Tobacco Settlement Revenue Oversight Committee

HIV, STD and Hepatitis Section Activities

Dominick Zurlo, M.A.
Hepatitis and Harm Reduction Program Manager
Public Health Division (PHD)

August 11, 2017

Harm Reduction and Hepatitis Program Support from Tobacco Settlement

	State fiscal year (SFY) 2017	SFY 2018	Request for SFY 2019
Hepatitis Program	\$43,400	\$43,400	\$60,000
Harm Reduction Program	\$249,600	\$249,600	\$383,000
Total	\$293,000	\$293,000	\$443,000



Harm Reduction and Hepatitis Program Support from Tobacco Settlement

**Hepatitis
Program**

**Tobacco settlement funds reflect
11% of total contractual dollars.**

**Harm
Reduction
Program**

**Tobacco settlement funds reflect
34% of total contractual dollars.**

Overall

**This support is essential.
The Harm Reduction Program
continues not to have
any federal support.**



Hepatitis Program

Select Accomplishments

- ❖ Public Health Offices (PHO) and contractual providers delivered the following services.
 - Over 4,600 laboratory tests for hepatitis B virus (HBV) and hepatitis C virus (HCV) were conducted in SF17.
 - Distributed over 4,100 doses of vaccines for hepatitis A and B in SFY16.
 - Innovative Under-30-Surveillance Project in CY16:
 - 1,156 identified cases of hepatitis C in persons under age 30 – most of which are likely very recent infections.
 - 847 were investigated, with 30% contacted for enhanced surveillance and interview
 - All were referred to needed services, including harm reduction sites to prevent passing HCV to others

Harm Reduction Program Accomplishments - Overview

- ❖ Statewide Syringe Services Program (SSP) activities are a fundamental and effective means of preventing the spread of HIV and hepatitis C virus (HCV).
 - Integrated approach for HIV and rapid HCV testing, including in correctional facilities, harm reduction outreaches, and community settings.
 - HCV rapid testing has been integrated into the HIV counseling, testing and referral services (CTRS) curriculum.
 - The SSP provides an access point for at-risk clients to navigation services into Hepatitis C treatment.

- ❖ The SSP provides access to at-risk clients for delivery of overdose prevention education and distribution of Naloxone (Narcan) for opiate overdoses.

Harm Reduction Program Accomplishments – Syringe Services

- ❖ Distributed over 6.75 million new syringes in SFY16.
- ❖ Collects 94% to 97% of distributed syringes annually
 - ❖ This does not include syringe collection drop-boxes
(an additional 400,00-600,000 syringes)
 - ❖ By removing used syringes from circulation, public safety is increased
- ❖ The number of clients served is growing quickly.
 - ❖ 2,817 in SFY 2012
 - ❖ 6,369 in SFY 2013
 - ❖ 6,139 in SFY 2014
 - ❖ 8,334 in SFY 2015
 - ❖ 9,050 in SFY 2016
- ❖ Between 84% and 86% of participants report not sharing syringes.

Harm Reduction Program Accomplishments – Treatment Referrals and Overdose Prevention

- ❖ Each year, more than 2/3 of SSP participants (68 – 71%) make one or more attempts to get into other substance use treatment programs. Of these attempts, roughly 1/3 experience barriers or challenges in receiving treatment.
- ❖ The overdose prevention program is growing rapidly. In CY 2016 naloxone was distributed to a total of 3,042 individuals, almost three times the 1,140 individuals who received naloxone in 2011.
- ❖ There were 769 overdose reversals in 2015 and 810 in 2016, where the person was reported “OK” afterwards. This is more than six (6) times the figure of 128 reversals in 2011.

